Psychedelics as Psychiatric Medications
March 1, 2023
Deborah C. Mash
1 citation
Abstract Ibogaine has been used as a botanical preparation from the root bark of Tabernanthe iboga for over one hundred years, both as a crude preparation and as semisynthetic ibogaine. Extracts derived from this plant have a long history of traditional medicinal and ceremonial use in Western Africa. Ibogaine is a polypharmacology drug that acts on several neurotransmitter systems, including...
Psychedelics as Psychiatric Medications
March 1, 2023
Mihai Avram, Felix Müller, Stefan Borgwardt
1 citation
Abstract Lysergic acid diethylamide (LSD) is a potent perception-altering chemical. Since the discovery of its effects almost eighty years ago, LSD has been revered and demonized. Before its ban in the late 1960s, LSD was used to model aspects of psychosis and treat distinct mental disorders such as alcohol addiction and anxiety. The new wave of research on psychedelics as potential treatments...
Psychedelics as Psychiatric Medications
March 1, 2023
Michael C Mithoefer, David E. Presti
Abstract MDMA (3,4-methylenedioxymethamphetamine) was originally synthesized and patented by the Merck chemical company in 1914. It was not explored for human use until the 1970–80s when there were published reports that it could be a useful catalyst to psychotherapy, in part because it often produced reduced anxiety and increased emotional openness. In 1985, in response to media attention to...
Psychedelics as Psychiatric Medications
March 1, 2023
David Castle, Nicole Ledwos, David Nutt
Abstract This is an exciting time for psychedelics and related drugs, with a renewed scientific interest in their potential benefits for a range of mental health disorders and addictions. However, much is yet to be discovered about this group of drugs, including precisely how they work in the brain; how their biological effects interact with psychological support to effect therapeutic change;...
Psychedelics as Psychiatric Medications
March 1, 2023
Joanna C. Neill, Mohammed Shahid, Rosalind Gittins et al.
Abstract Improved understanding of the potential risks and adverse effects of psychedelics is essential before psychedelic-assisted therapy is adopted into mainstream medicine. In spite of numerous recent clinical trials, gaps in knowledge remain. A comprehensive analysis of human receptor pharmacology is required to inform clinical dosing strategies and improve the understanding of drug-drug...
Psychedelics as Psychiatric Medications
March 1, 2023
James Linden, Daniel Robin
Abstract This chapter will detail some of the lesser-known psychedelics. While lesser known, some of these are arguably the most potent molecules, and one could argue these hold the most potential for medicine. We will go on a small journey into a lesser-understood corner of plant medicine and psychedelics. Many of the psychedelics discussed so far in this publication have well-elucidated and...
Psychedelics as Psychiatric Medications
March 1, 2023
Daniel Perkins, Simon Ruffell, Jerome Sarris
Abstract Ayahuasca is a psychedelic plant brew originating in the Amazon basin. It is typically made from two basic components: the ayahuasca vine (Banisteriopsis caapi), containing various harmala alkaloids, and the leaves of a plant containing the potent psychedelic dimethyltryptamine (DMT), such as the chacruna plant (Psychotria viridis). Evidence suggests the brew has been used for at least...
Psychedelics as Psychiatric Medications
March 1, 2023
Laurie Higbed, Ben Sessa
Abstract Psychedelic compounds offer a unique type of mental health treatment. This chapter considers how psychedelics can be explored as an alternative to the typical maintenance medication for the treatment of symptoms, through using psychedelic medicines in a controlled clinical setting as an adjunct to psychotherapy. In combination with psychotherapy, the psychedelic experience provides the...